-
ENDO Data – Prostate-Specific Membrane Antigen (PSMA) Expression in Cytologically Indeterminate and Malignant Thyroid Nodules
-
ENDO Data – Retrospective Analysis of mRNA Expression Based Signatures of Thyroid Tumor Invasion and Metastases
-
AACE Data: Efficacy of Radiofrequency Ablation for Afirma Genomic Sequencing Classifier (GSC) Benign Indeterminate Thyroid Nodules
-
AACE Data: First Report of Pre-Operative Detection of Two TERT Promoter Mutations Within a Papillary Thyroid Carcinoma
-
JCEM Data: Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay
-
ATA Data: Sodium Iodide Symporter (NIS) Expression in Cytologically Indeterminate and Malignant Thyroid Nodules
-
ATA Data: Molecular Assessment of Isthmus Thyroid Carcinomas
-
ATA Data: Leveraging RNA Sequencing for Pre-Operative Immunophenotyping of BRAFV600E+ Thyroid Nodules
-
ENDO Data: Cytologic and Molecular Assessment of Isthmus Thyroid Nodules
-
AACE Data – Histopathology of Telomerase Reverse Transcriptase Promoter (TERT) Mutated Indeterminate Thyroid Nodules
-
JCEM data – Real world performance of the Afirma Genomic Sequencing Classifier (GSC) – a meta analysis
-
Thyroid – Preoperative identification of medullary thyroid carcinoma (MTC): Clinical validation of the Afirma MTC RNA-Sequencing classifier
-
Cancer Cytopathology – The Afirma Xpression Atlas for Thyroid Nodules and Thyroid Cancer Metastases: Insights to Inform Clinical Decision-Making from a Fine-Needle Aspiration Sample
-
ENDO Oral Data – Identification of Novel and Rare Receptor Tyrosine Kinase Fusions in Thyroid Fine Needle Aspirates
(ENDO 2020 canceled due to COVID-19)
-
ENDO Data – Positive Predictive Value of TP53 Variants in Bethesda III/IV Thyroid Fine-Needle Aspirates
(ENDO 2020 canceled due to COVID-19)
-
JCEM – Real World Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules (Cleveland Clinic)
-
Cancer Cytopathology – Performance of the Afirma Genomic Sequencing Classifier Versus Gene Expression Classifier: An Institutional Experience (Fox Chase)
-
Frontiers in Endocrinology – Afirma Xpression Atlas Clinical & Analytical Validation Study
-
Thyroid Journal – Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules
-
ASCO Data – New Afirma Data Shows Potential to Guide Targeted Treatment for Medullary Thyroid Cancer
-
Thyroid Journal – Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules (B&W)
-
Cancer Cytopathology – Extending expressed RNA genomics from surgical decision making for cytologically indeterminate thyroid nodules to targeting therapies for metastatic thyroid cancer
-
BMC Systems Biology – Identification of Hürthle Cell Cancers: Solving a Clinical Challenge with Genomic Sequencing and a Trio of Machine Learning Algorithms
-
ENDO Data – New Afirma Xpression Atlas Data Advances Genomic Understanding of Medullary Thyroid Cancer
-
Endocrine Practice – Statistical Comparison of Afirma GSC and Afirma GEC Outcomes in a Community Endocrine Surgical Practice: Early Findings (Memorial Healthcare)
-
ATA Data – Interview with Christian Nasr, MD: Performance of Afirma Genomic Sequencing Classifier: The Initial Cleveland Clinic Experience
-
ATA Data – Interview with Erik Alexander, MD: Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules
-
ATA Data – Interview with Jennifer A. Sipos, MD: Experience with the Genomic Sequencing Classifier in >100 Cytologically Indeterminate Thyroid Nodules
-
Interview with R. Mack Harrell, MD: Afirma GSC: Early Endocrine Surgery Practice Performance 8/2017-2/2018
-
Interview with Peter M. Sadow, MD, PhD: Detecting Expressed Variants and Fusions in RNASeq Data from Thyroid FNAs
-
Interview with Christian Nasr, MD: Independent Academic Medical Center Afirma GSC Experience
-
Interview with Joshua Babiarz, PhD: The Mutational Landscape of 774 Variants and 132 Fusions in 513 Genes Measured in Thyroid FNAs from a Multicenter Blinded Cohort
March 2018
-
Interview with Michael Shanik, MD: Afirma Genomic Sequencing Classifier Experience Among the First 5478 Consecutive Samples
March 2018
-
Interview with R. Mack Harrell, MD: Reduced Surgery through Afirma GEC: Impact to date and potential for the future
May 2017
-
Interview with Brian Michael, MD: Six-year Clinical and Imaging Follow-up of an Office-based Gene Expression Classifier
May 2017
-
Interview with Whitney Goldner, MD: Institutional Experience with Afirma GEC after Repeat Biopsy
April 2017
-
Interview with Matthew J. Levine, MD, FACE: Five Year Experience with Afirma Gene Expression Classifier (GEC)
September 2016
-
Interview with Jennifer A. Sipos, MD: Long-Term Follow-Up of Afirma GEC Benign Results
September 2016
-
Interview with Ying Hu, MD, PhD: More Incidental Thyroid Malignancies Observed in the Lobes with a GEC Suspicious Nodule
September 2016
-
UCLA Study Evaluates Whether Afirma GEC Has Refined the Indeterminate Cytology Category
May 2016
-
New Multicenter Long-term Outcome Study Demonstrates Durable Afirma GEC Benign Results
March 2016
-
New Long-Term Follow-Up Study Demonstrates that Afirma GEC Benign Nodules Behave Similarly to Nodules with Benign Cytology
January 2016
-
Nine New Studies Demonstrate Utility and Long-Term Durability of Afirma GEC (Gene Expression Classifier)
November 2015
-
Case Study: Genomic Analysis Identifies Medullary Thyroid Carcinoma
May 2015
